Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Mina Tempaku"'
Autor:
Akiko Eguchi, Motoh Iwasa, Ryosuke Sugimoto, Mina Tempaku, Kyoko Yoshikawa, Naohiko Yoshizawa, Davide Povero, Kazushi Sugimoto, Hiroshi Hasegawa, Yoshiyuki Takei, Hayato Nakagawa
Publikováno v:
Hepatology Communications, Vol 6, Iss 12, Pp 3515-3527 (2022)
Abstract Complement complex 1 subunit q (C1q) has multiple functions, including cell migration, in addition to its traditional complement‐activating effect. Research shows C1q is a ligand for frizzled receptors (FZDs). FZD‐induced yes‐associate
Externí odkaz:
https://doaj.org/article/f777e468e1c34e10996bb4629e88fc8c
Autor:
Yasuyuki Tamai, Akiko Eguchi, Ryuta Shigefuku, Hiroshi Kitamura, Mina Tempaku, Ryosuke Sugimoto, Yoshinao Kobayashi, Motoh Iwasa, Yoshiyuki Takei, Hayato Nakagawa
Publikováno v:
eLife, Vol 11 (2022)
Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarco
Externí odkaz:
https://doaj.org/article/9d9ad1ffcbca4c8bab44dc5bb9f59cc8
Autor:
Akiko Eguchi, Motoh Iwasa, Yasuyuki Tamai, Minori Yamada, Koji Okuno, Ryuta Shigefuku, Kyoko Yoshikawa, Mina Tempaku, Koji Sakaguchi, Hideaki Tanaka, Kazushi Sugimoto, Yoshinao Kobayashi, Tetsuji Yamaguchi, Hayato Nakagawa
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFragmented cytokeratin 18 (fCK18) is released from damaged hepatocytes undergoing apoptosis and is recognized as a liver condition biomarker. We have developed a highly sensitive serum fCK18 CLEIA and reported that serum levels of this casp
Externí odkaz:
https://doaj.org/article/90440dda7ad3409da730080b9aa93306
Autor:
Yoshinao Kobayashi, Akiko Eguchi, Yasuyuki Tamai, Sanae Fukuda, Mina Tempaku, Kiyora Izuoka, Motoh Iwasa, Yoshiyuki Takei, Kenji Togashi
Publikováno v:
Frontiers in Physiology, Vol 12 (2021)
Introduction/PurposeHigh-intensity interval training (HIIT) promotes various biological processes and metabolic effects in multiple organs, but the role of extracellular vesicles (EVs) released from a variety of cells is not fully understood during H
Externí odkaz:
https://doaj.org/article/419302c79db94d898840e6a1d0886d20
Autor:
Ryuta Shigefuku, Motoh Iwasa, Akiko Eguchi, Mina Tempaku, Yasuyuki Tamai, Naoto Fujiwara, Ryosuke Sugimoto, Hideaki Tanaka, Kazushi Sugimoto, Yoshinao Kobayashi, Hayato Nakagawa
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 1, p31-41, 11p
Autor:
Ryuta Shigefuku, Motoh Iwasa, Akiko Eguchi, Mina Tempaku, Yasuyuki Tamai, Naoto Fujiwara, Ryosuke Sugimoto, Hideaki Tanaka, Kazushi Sugimoto, Yoshinao Kobayashi, Hayato Nakagawa
Publikováno v:
Internal Medicine.
Autor:
Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Hiroshi Kitamura, Mina Tempaku, Ryosuke Sugimoto, Yoshinao Kobayashi, Motoh Iwasa, Yoshiyuki Takei, Hayato Nakagawa
Publikováno v:
eLife. 11
Background:Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcop
Autor:
Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Hiroshi Kitamura, Mina Tempaku, Ryosuke Sugimoto, Yoshinao Kobayashi, Motoh Iwasa, Yoshiyuki Takei, Hayato Nakagawa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::261dc9cf82ee4cf7be182b85de87fcd1
https://doi.org/10.7554/elife.80638.sa2
https://doi.org/10.7554/elife.80638.sa2
Autor:
Yasuyuki Tamai, Akiko Eguchi, Ryuta Shigefuku, Hiroshi Kitamura, Mina Tempaku, Ryosuke Sugimoto, Yoshinao Kobayashi, Motoh Iwasa, Yoshiyuki Takei, Hayato Nakagawa
[Background & aims] Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate, however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83e42d31cb0364872efd31ecc395744c
https://doi.org/10.1101/2022.06.14.22276395
https://doi.org/10.1101/2022.06.14.22276395
Autor:
Motoh Iwasa, Tatsuya Suzuki, Yasuyuki Tamai, Ryuta Shigefuku, Akiko Eguchi, Yoshiyuki Takei, Mina Tempaku
Publikováno v:
Internal Medicine
Background: The efficacy of tolvaptan, an orally active vasopressin V2-receptor antagonist, has recently been reported in patients with massive ascites unresponsive to conventional diuretics. However, the effect of tolvaptan varies among patients. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b9910e9ad311803f756719622528e9
https://doi.org/10.21203/rs.3.rs-52252/v2
https://doi.org/10.21203/rs.3.rs-52252/v2